Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.

Cancer research - 1 Mar 1993

Chang A E, Yoshizawa H, Sakai K, Cameron M J, Sondak V K, Shu S

Abstract excerpt

The adoptive immunotherapy of human malignancy requires reliable methods to sensitize and expand patients' T-cells reactive to autologous tumors. In animal studies, we have generated therapeutic effector cells against a poorly immunogenic tumor by a two-step procedure: vaccination of the host followed by the secondary stimulation of vaccine-primed lymph node (LN) cells by in vitro sensitization (IVS) with tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antigens, Neoplasm
Share to Cytotoxicity, Immunologic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Lymph Nodes

Share to Melanoma

Share to Neoplasms

Share to Phenotype

Source

Identifiers

PMID: 8439951

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.PMID 8439951Read ↗

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.Semantic proximity Read ↗

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.Semantic proximity Read ↗

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.Semantic proximity Read ↗

Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.Semantic proximity Read ↗

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer.Semantic proximity Read ↗

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.Semantic proximity Read ↗

Immunological effects of BCG as an adjuvant in autologous tumor vaccines.Semantic proximity Read ↗

Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.Semantic proximity Read ↗

Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.Semantic proximity Read ↗

Cancer vaccines: moving beyond current paradigms.Semantic proximity Read ↗

Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma.Semantic proximity Read ↗

High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.